The company's performance was anchored by its Life Sciences Services segment, which saw a 15% year-over-year revenue increase. Within this division, BioStorage and BioServices experienced a 25% surge, reflecting heightened global demand for secure, temperature-controlled handling of sensitive biological materials. As of June 30, 2026, Cryoport supported 779 clinical trials worldwide, a net increase of 51 trials over the previous year, alongside 22 commercially approved cell and gene therapies.

CEO Jerrell Shelton emphasized that the move to positive adjusted EBITDA of $0.4 million represents a critical step in the firm’s long-term financial strategy. While the company recorded a net loss of $8.3 million for the quarter, this figure marks an improvement over the $12 million loss sustained in the same period last year. Looking ahead, Cryoport is preparing to launch new operations at its Global Supply Chain Centers in Paris and Santa Ana, California, in the fourth quarter of 2026. These expansions are intended to further scale the business and capitalize on the maturation of the cell and gene therapy market.